Patients are telling the truth — just not to you
September 21, 2026 | Data, Social Listening, clinical trials, patients
Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.
There’s a familiar complaint in clinical research: patients don’t open up. They say they’re fine when they’re not. They under-report side effects. They nod through the consent conversation, and months later it’s clear they didn’t really follow it.
Spend an hour where patients talk to each other, though, and a different picture appears. They’re not guarded at all. They’re astonishingly honest — about what they fear, the side effects they hide, the days they can barely function. The truth isn’t missing. It’s just pointed somewhere other than the clinic.
That gap between what patients share with one another and what they tell the people providing their care is worth paying attention to. Because the things they don’t say out loud are usually the things a trial team most needs to hear.
What we miss in the room
It’s in patient communities where the quiet parts get said out loud.
On what it takes just to turn up, one person, deep into fertility treatment, wrote that they’d been going so long they had a favourite parking spot and no longer knew how to answer “how are you?” — “I am fine. I am functional.” The “fine” is doing a lot of work there.
On side effects, the honesty is sharper — and more uncomfortable. One cancer patient described hiding their symptoms “so I don’t have to wait another month for the next dose”.
Someone managing chronic pain put it plainly: they don’t tell the doctor about something that helps, “otherwise I’m an addict and not someone who needs help”. That isn’t non-compliance. It’s a calculation — that telling the truth might cost them their treatment.
Patients can also recognise when something isn’t right, sometimes before the clinical picture becomes clear. “The night of the procedure, I knew something was wrong,” one wrote — a concern later confirmed by the tests.
Some of this never gets said in the room. Some of it is said but not fully heard. All of it has value.
The silence isn’t soft — it shows up in your data
It’s tempting to file this under bedside manner. It isn’t. When patients don’t feel safe being honest, the consequences land exactly where a trial can least afford them.
Under-reported side effects create blind spots in safety data. The signals are there, they just aren’t always reaching you. Distress only becomes visible when someone quietly drops out. The burden of participation appears later as missed visits and withdrawals that seem to come from nowhere. A patient saying “I’m fine” isn’t a small social grace; it’s a missing data point. Honesty, in other words, isn’t a courtesy patients owe you. It’s the integrity of what you’re collecting.
Honesty is a design choice, not a personality trait
Patients aren’t withholding because they’re difficult or private. They’re withholding because, somewhere along the way, they learned that honesty has a cost — you lose the drug, you get dismissed, you become “the difficult one”, you worry people who already look worried.
So, the fix isn’t asking harder. It’s making honesty feel safer. That’s a design problem, and it runs through everything a participant touches: how a question is asked, how a reported side effect is met, whether the consent conversation invited questions or just collected a signature, whether the materials treat someone as an expert in their own condition or a beginner. Get those right and people tell you more, not because they suddenly trust strangers, but because the room made candour feel safer.
Start by listening where they’re already honest
If you want to understand what your participants aren’t saying, start where they’re already talking.
The version of the trial experience that rarely reaches the clinic already exists — in the open, in the communities where patients talk to one another. It will tell you which side effects people hide and why, what attending really costs, where the consent process loses them, and what they wish someone had asked. It’s the brief for every conversation you then design.
You don’t need to give people permission to speak openly in the abstract. Start by listening to what they’re already comfortable saying elsewhere. Then build the conditions where they’ll feel just as comfortable saying it to you.
Ready to talk?
Understanding what patients aren’t saying — and designing the materials and moments that help them say it — is what we do. If you want the real version of your participants’ experience, not just the version they feel able to share in clinic, let’s talk.
The patient voice here is drawn from public patient communities in our listening index, de-identified and lightly trimmed; medication names removed. It’s a self-selected, anonymous source — illustrative, not statistically representative — but it shows, in patients’ own words, the honest version they rarely say in clinic.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
AI and away we go: key insights from Reuters Pharma 2025
AI is revolutionising the pharmaceutical industry, as highlighted at Reuters Pharma 2025, with transformative applications across marketing, drug discovery, and patient engagement, despite challenges in adoption, regulation, and data trust.
Exciting updates from our content and strategy team
Cuttsy+Cuttsy celebrates new beginnings with the appointment of Oli Bailey as Strategy Director and recognises team excellence through several well-deserved promotions.
How is generative AI transforming clinical trials?
Discover how generative AI is revolutionising clinical trials, from enhancing patient recruitment to improving data analysis.
Content for all – how to connect with neurodiverse audiences
Discover essential strategies for crafting inclusive and accessible written content tailored for neurodivergent readers.
Cuttsy+Cuttsy launches ccura: AI powered, always human
Cuttsy+Cuttsy introduces ccura, an AI-powered healthcare communications platform that blends technology with human expertise to enhance collaboration, streamline workflows, and deliver patient-focused, high-quality solutions with security and compliance at its…
Two Sides of the Same Coin: Patient Engagement vs Patient Involvement
Unpack the difference between patient engagement and patient involvement.
Cuttsy+Cuttsy achieves Platinum accreditation from Investors in People
Cuttsy+Cuttsy is proud to have achieved a Platinum accreditation from Investors in People, placing them among the top 2% of organisations assessed globally.
Cuttsy+Cuttsy awarded Gold EcoVadis sustainability rating
Cuttsy+Cuttsy proudly announces their Gold Medal achievement from EcoVadis for 2024, placing them among the top 5% of companies assessed and within the 97th percentile, a testament to their unwavering…
Age is not just a number when it comes to clinical trials
In this blog we look at the critical underrepresentation of older adults in clinical trials, emphasising the need for inclusive trial designs and targeted strategies to ensure safe and effective…
How to boost clinical trial access and make patients health-empowered
Clinical research is becoming more patient-centric, but there’s still more that needs to be done to make clinical trials available to everyone. This could include wider participation.